In that trial, a high risk of recurrence was defined as 4 or more positive axillary lymph nodes (ALNs), or 1–3 positive ALNs, high Ki-67 index (≥ 20%), and either histological grade 3 or tumor size ≥ 5 cm2. This evidence concerns the gene MKI67 and neoplasm.